Memphis-based Medtronic Spine has seen a $21 million drop due to its Infuse bone graft device. Device sales have declined sharply after patients have spoken out about Infuse side effects at the same time the company faces allegations that it hid information about the risks associated with the device.
The Medtronic Infuse has been linked to several bone graft side effects, including paralysis, excessive bone growth and retrograde ejaculation. Several patients have filed Infuse lawsuits alleging that the company released a defective device.
Medtronic is also facing allegations that it promoted the device for off-label use, which may have led to additional side effects. A U.S. Senate investigation concluded that Medtronic helped author device studies that downplayed the risks and side effects associated with the Infuse bone graft device.